Tianjin Lisheng Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 17.92%

Tianjin Lisheng Pharmaceutical Co Ltd (002393) has an Asset Resilience Ratio of 17.92% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 002393 working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥991.31 Million

≈ $145.06 Million USD Cash + Short-term Investments

Total Assets

CN¥5.53 Billion

≈ $809.66 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2022–2025)

This chart shows how Tianjin Lisheng Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Tianjin Lisheng Pharmaceutical Co Ltd.

Liquid Assets Composition Over Time

This chart breaks down Tianjin Lisheng Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Tianjin Lisheng Pharmaceutical Co Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥991.31 Million	17.92%
Total Liquid Assets	CN¥991.31 Million	17.92%

Asset Resilience Insights

Good Liquidity Position: Tianjin Lisheng Pharmaceutical Co Ltd maintains a healthy 17.92% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Tianjin Lisheng Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Tianjin Lisheng Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Yunnan Baiyao Group Co Ltd SHE:000538	Drug Manufacturers - Specialty & Generic	8.38%
Guangdong Zhongsheng Pharmaceutical Co Ltd SHE:002317	Drug Manufacturers - Specialty & Generic	6.62%
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Harbin Gloria Pharmaceuticals SHE:002437	Drug Manufacturers - Specialty & Generic	9.04%
Jiuzhitang Co Ltd SHE:000989	Drug Manufacturers - Specialty & Generic	7.86%
Renhe Pharmacy Co Ltd SHE:000650	Drug Manufacturers - Specialty & Generic	37.54%
Jiangsu Kanion Pharmaceutical Co Ltd SHG:600557	Drug Manufacturers - Specialty & Generic	0.29%

Annual Asset Resilience Ratio for Tianjin Lisheng Pharmaceutical Co Ltd (2022–2025)

The table below shows the annual Asset Resilience Ratio data for Tianjin Lisheng Pharmaceutical Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	18.27%	CN¥1.02 Billion ≈ $149.30 Million	CN¥5.58 Billion ≈ $817.17 Million	+8.36pp
2024-12-31	9.91%	CN¥573.36 Million ≈ $83.90 Million	CN¥5.79 Billion ≈ $846.60 Million	+5.91pp
2023-12-31	4.00%	CN¥231.26 Million ≈ $33.84 Million	CN¥5.78 Billion ≈ $845.88 Million	+0.21pp
2022-12-31	3.79%	CN¥200.32 Million ≈ $29.31 Million	CN¥5.29 Billion ≈ $774.25 Million	--

pp = percentage points

About Tianjin Lisheng Pharmaceutical Co Ltd

SHE:002393 China Drug Manufacturers - Specialty & Generic

Market Cap

$613.09 Million

CN¥4.19 Billion CNY

Market Cap Rank

#11299 Global

#3165 in China

Share Price

CN¥13.59

Change (1 day)

+1.04%

52-Week Range

CN¥13.44 - CN¥24.25

All Time High

CN¥46.19